2-B-P-055 〇鳥内 皐暉¹、木原 星衣¹、青木 啓将¹、竹下 覚^1,2、垣田 博樹^1,2、山田 恭聖²、青山 峰芳¹ Toriuchi Kohki¹, Toshie Kihara¹, Hiromasa Aoki¹, Satoru Takeshita^1,2, Hiroki Kakita^1,2, Yasumasa Yamada², Mineyoshi Aoyama^{1 1}名古屋市立大・院薬・病態解析、²愛知医科大・新生児集中治療部門 ¹Department of Pathobiology, Graduate School of Pharmaceutical Sciences, Nagoya City University, ²Department of Perinatal and Neonatal Medicine, Aichi Medical University [Background]Atherosclerosis results from vascular endothelial cell injury caused by lipid metabolites deposition in the vessel wall, leading to myocardial and cerebral stroke. Early detection and treatment are difficult because of the lack of clinical symptoms in the early stages. MicroRNAs (miRNAs) regulate the expression of target mRNAs and have attracted attention as diagnostic biomarkers. In this study, we focused on the adhesion between monocytes and endothelial cells in the early stage of atherosclerosis. We examined the relationship between miRNAs and changes in endothelial-monocyte adhesion induced by IL-1β. 
[Results]We found that hsa-miR-1914-5p was decreased by IL-1β stimulation in human vascular endothelial cell line EA.hy926 or monocytic cell line THP-1. Endothelial-monocyte adhesion and expression of adhesion factors were significantly increased under both IL-1β-stimulated and hsa-miR-1914-5p inhibitory conditions. Furthermore, overexpression of hsa-miR-1914-5p significantly suppressed IL-1β-induced adhesion. 
[Conclusion] These results suggest that hsa-miR-1914-5p may suppress endothelial-monocyte adhesion, thereby reducing the progression of early lesions in atherosclerosis. These findings are expected to lead to the development of novel therapies for atherosclerosis targeting hsa-miR-1914-5p as well as its application as a biomarker.